Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis
Authors:
- Gabriela M BaerlocherGBGabriela M Baerlocher
- Bart BuringtonBBBart Burington
- David S SnyderDSDavid S Snyder
- 24 December 2015
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 373 (26) , 2579-2581
Abstract
To the Editor: Baerlocher et al. (Sept. 3 issue)1 report on telomere-targeted treatment with imetelstat in 18 patients with essential thrombocythemia. The drug was effective in controlling platelet levels in all patients, albeit often at the expense of hemoglobin and neutrophil levels. However, the other main treatment goals in essential thrombocythemia2 — controlling symptoms and preventing both disease progression and thromboembolic complications — were definitely not achieved. Fatigue, diarrhea, and nausea were all reported by more than 70% of the patients. A total of 3 patients had progression to myelofibrosis, and 2 patients had a thromboembolic event. Thus, treatment with . . .Keywords
This publication has 11 references indexed in Scilit:
- A Pilot Study of the Telomerase Inhibitor Imetelstat for MyelofibrosisNew England Journal of Medicine, 2015
- Telomerase Inhibitor Imetelstat in Patients with Essential ThrombocythemiaNew England Journal of Medicine, 2015
- Treating Myeloproliferation — On Target or Off?New England Journal of Medicine, 2015
- Antisense Oligonucleotide TherapiesToxicologic Pathology, 2014
- Interferon Alfa Therapy in CALR-Mutated Essential ThrombocythemiaNew England Journal of Medicine, 2014
- JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drugHaematologica, 2013
- Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosisExpert Review of Hematology, 2013
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNetJournal of Clinical Oncology, 2011
- Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cellsLeukemia, 2010
- Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remissionHematology, 2009